logo
Plus   Neg
Share
Email

Basilea Reaches Agreement With Roche On Planned Study In Gastric Cancer

Basilea Pharmaceutica said Wednesday that it extended its clinical supply agreement with Roche to explore a combination of Basilea's panFGFR kinase inhibitor derazantinib and Roche's atezolizumab in patients with gastric (stomach) cancer.

The initial clinical supply agreement covered urothelial (bladder) cancer and was concluded in January 2019.

Basilea expects to start a biomarker-driven multi-cohort phase 1/2 study in advanced gastric cancer patients with FGFR genetic aberrations in the third quarter of 2020. The study will assess the efficacy and safety of derazantinib as mono- and combination therapy in the second-line setting.

Basilea will be the sponsor of the study and Roche will provide clinical supply of atezolizumab, a PD-L1 checkpoint inhibitor.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Apple Inc. (AAPL) said it doesn't expect to meet its revenue guidance for the second quarter due to lower smartphone demand, and temporary work slowdowns related to coronavirus outbreak in China. Textron Specialized Vehicles recalled 20,573 units of Gas-powered E-Z-GO, Cushman and Tracker brand off-road vehicles for possible fire hazard, a statement by the U.S. Consumer Product Safety Commission said. The company said starter generator wire can be improperly secured, allowing it to come into contact with the vehicle's exhaust that could cause a fire hazard. Delta Air Lines Inc. said Friday that it will invest $1 billion over the next decade to mitigate all greenhouse gas emissions from its global business, starting March 1, 2020. The company intends to become the first airline in the world to go carbon neutral. The airline said that over the next decade, it will spend $1 billion to drive innovation and advance clean-air travel technologies.
RELATED NEWS
Follow RTT
>